Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:IDYA

IDEAYA Biosciences Q3 2026 Earnings Date & Estimates

IDEAYA Biosciences logo
$34.26 -1.80 (-4.99%)
Closing price 04:00 PM Eastern
Extended Trading
$34.90 +0.64 (+1.88%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEAYA Biosciences is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for November 4, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from IDEAYA Biosciences in Q3 2026

IDEAYA Biosciences is expected to post earnings of -$1.17 per share on revenue of $6.84 million. In the same quarter a year earlier IDEAYA Biosciences reported $1.33 per share on revenue of $207.83 million. IDEAYA Biosciences last reported on August 4, 2026, posting -$1.22 per share and missing the -$1.06 consensus estimate. IDEAYA Biosciences has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.17
Expected Revenue
$6.84 million
Prior-Year EPS
$1.33
Prior-Year Revenue
$207.83 million
Expected EPS Growth
-188.0%
Expected Revenue Growth
-96.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.22 (Missed by -$0.16)
Last Quarter Revenue
$8.86 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

IDEAYA Biosciences Q3 2026 Earnings FAQ

IDEAYA Biosciences (NASDAQ:IDYA) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

IDEAYA Biosciences' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect IDEAYA Biosciences to post earnings of -$1.17 per share for Q3 2026.

The consensus revenue estimate for IDEAYA Biosciences is $6.84 million for Q3 2026.

IDEAYA Biosciences Earnings Headlines

IDEAYA Biosciences (NASDAQ:IDYA) vs. Sangamo Therapeutics (NASDAQ:SGMO) Head to Head Review
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098896
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
September 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ideaya-biosciences-announces-the-promotion-of-dr-michael-white-to-president-research-and-development-302890666.html
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
October 13 at 1:00 AM  |  Stansberry Research (Ad)
Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?
September 25, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/can-ideaya-biosciences-idya-turn-uncharted-oncology-territory-into-commercial-gold-1843883/
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302889869.html
Analysts Are Bullish on Top Healthcare Stocks: Xenon (XENE), IDEAYA Biosciences (IDYA)
September 19, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IDYA/pressreleases/4693181/analysts-are-bullish-on-top-healthcare-stocks-xenon-xene-ideaya-biosciences-idya/
See More IDEAYA Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IDEAYA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IDEAYA Biosciences and other key companies, straight to your email.

About IDEAYA Biosciences

IDEAYA Biosciences (NASDAQ:IDYA) is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company uses insights from tumor biology, cancer genetics and synthetic lethality to identify treatments designed to target specific molecular alterations in tumors.

Its development pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily in genetically defined cancers, including GNAQ- or GNA11-mutated uveal melanoma. IDEAYA is also developing IDE397, an investigational MAT2A inhibitor intended for cancers with MTAP deletions, along with additional discovery and development programs targeting genetically selected tumors.

Founded in 2015 and headquartered in South San Francisco, California, IDEAYA conducts research and clinical development activities through collaborations and clinical studies intended to serve patients in multiple international markets. The company’s programs remain investigational, and their safety and effectiveness have not been established for general use.

View IDEAYA Biosciences Profile
Earnings Tools